Seres Therapeutics
Seres Therapeutics' oral Firmicutes spore fraction, co-marketed with Nestle Health Science, was FDA-approved in April 2023 for recurrent CDI prevention — the first oral LBP, opening large-scale investment into the sector.
- Country
- United States
- Ticker
- NASDAQ:MCRB
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Microbiome therapeutics (live biotherapeutic products) | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.